JP2011518119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518119A5 JP2011518119A5 JP2010550224A JP2010550224A JP2011518119A5 JP 2011518119 A5 JP2011518119 A5 JP 2011518119A5 JP 2010550224 A JP2010550224 A JP 2010550224A JP 2010550224 A JP2010550224 A JP 2010550224A JP 2011518119 A5 JP2011518119 A5 JP 2011518119A5
- Authority
- JP
- Japan
- Prior art keywords
- 4pba
- combination according
- pharmaceutically acceptable
- brain
- inducer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OBKXEAXTFZPCHS-UHFFFAOYSA-N gamma-phenylbutyric acid Natural products OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 9
- OBKXEAXTFZPCHS-UHFFFAOYSA-M 4-phenylbutyrate Chemical compound [O-]C(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-M 0.000 claims 7
- 208000037259 Amyloid Plaque Diseases 0.000 claims 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 5
- 210000004556 brain Anatomy 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 230000008030 elimination Effects 0.000 claims 4
- 238000003379 elimination reaction Methods 0.000 claims 4
- 239000000411 inducer Substances 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical group OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims 2
- -1 4PBA sodium salt Chemical class 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001925 catabolic effect Effects 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims 1
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 claims 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical group C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims 1
- 102100021496 Insulin-degrading enzyme Human genes 0.000 claims 1
- 102100028782 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005228 clioquinol Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200800736 | 2008-03-13 | ||
| ES200800736A ES2332687B1 (es) | 2008-03-13 | 2008-03-13 | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| PCT/ES2009/000121 WO2009112609A1 (es) | 2008-03-13 | 2009-03-06 | Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518119A JP2011518119A (ja) | 2011-06-23 |
| JP2011518119A5 true JP2011518119A5 (enExample) | 2012-04-26 |
Family
ID=40691368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550224A Withdrawn JP2011518119A (ja) | 2008-03-13 | 2009-03-06 | ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110027251A1 (enExample) |
| EP (1) | EP2272515A1 (enExample) |
| JP (1) | JP2011518119A (enExample) |
| CN (1) | CN102036665A (enExample) |
| AU (1) | AU2009224613A1 (enExample) |
| BR (1) | BRPI0909745A2 (enExample) |
| CA (1) | CA2718463A1 (enExample) |
| ES (1) | ES2332687B1 (enExample) |
| MX (1) | MX2010009933A (enExample) |
| RU (1) | RU2010138638A (enExample) |
| WO (1) | WO2009112609A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080827A1 (es) * | 2010-04-06 | 2012-05-09 | Bayer Cropscience Ag | Utilizacion del acido 4- fenil- butirico y/o de sus sales para el aumento de la tolerancia al estres en plantas |
| CN101973868B (zh) * | 2010-11-12 | 2012-08-15 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅰ型结晶及其制备方法 |
| EP2599479A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-phenylbutyric acid for the treatment of alzheimer's disease |
| WO2013149091A1 (en) | 2012-03-29 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Composition and method for treating neurodegenerative disease |
| CN102757334B (zh) * | 2012-07-30 | 2014-05-28 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅱ型晶体及其制备方法 |
| US9872865B2 (en) * | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| EP3019865A4 (en) * | 2013-07-12 | 2017-04-05 | Immuneering Corporation | Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition |
| US11224668B2 (en) * | 2016-02-29 | 2022-01-18 | Neurovation Labs, Inc. | Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD |
| IL296490B1 (en) | 2016-03-15 | 2025-09-01 | Acer Therapeutics Inc | Tasty compositions containing sodium phenylbutyrate and their uses |
| JP6962572B2 (ja) * | 2016-03-18 | 2021-11-05 | 学校法人同志社 | ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤 |
| JP2019214546A (ja) * | 2018-06-11 | 2019-12-19 | 学校法人福岡大学 | 終末糖化産物生成抑制剤及び医薬組成物 |
| JP2020083827A (ja) * | 2018-11-27 | 2020-06-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | ケミカルシャペロンまたは神経細胞死の抑制剤 |
| WO2020139874A1 (en) * | 2018-12-27 | 2020-07-02 | Virginia Polytechnic Institute And State University | Chemically programmed neutrophils and uses thereof |
| US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| US20240108593A1 (en) * | 2020-12-07 | 2024-04-04 | University Of Miami | Method of treating polyamine imbalance-related disorders |
| JP2024543053A (ja) * | 2021-11-08 | 2024-11-19 | アミーリクス・ファーマシューティカルズ・インコーポレイテッド | 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ |
| US12138272B2 (en) | 2022-05-12 | 2024-11-12 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| CN116099003A (zh) * | 2022-11-28 | 2023-05-12 | 核工业总医院 | 内质网应激抑制剂在放射性认知功能障碍药物中的应用 |
| WO2024165757A1 (en) | 2023-02-10 | 2024-08-15 | Ludwig-Maximilians-Universität München | Oral phenylbutyrate for treatment of human 4-repeat tauopathies |
| CN117338763A (zh) * | 2023-11-01 | 2024-01-05 | 重庆医科大学 | 丁酸钠在制备治疗帕金森病的药物中的应用及其治疗新靶标 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
| DE69706566T2 (de) * | 1996-08-13 | 2002-07-11 | P.N. Gerolymatos S.A., Kruoneri | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit |
| WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
| US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| WO2002090534A1 (en) * | 2001-05-02 | 2002-11-14 | The Regents Of The University Of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
| EP1482962A4 (en) * | 2002-02-15 | 2009-12-23 | Sloan Kettering Inst Cancer | METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX) |
| WO2009133128A1 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
-
2008
- 2008-03-13 ES ES200800736A patent/ES2332687B1/es not_active Withdrawn - After Issue
-
2009
- 2009-03-06 BR BRPI0909745A patent/BRPI0909745A2/pt not_active IP Right Cessation
- 2009-03-06 WO PCT/ES2009/000121 patent/WO2009112609A1/es not_active Ceased
- 2009-03-06 JP JP2010550224A patent/JP2011518119A/ja not_active Withdrawn
- 2009-03-06 MX MX2010009933A patent/MX2010009933A/es unknown
- 2009-03-06 RU RU2010138638/15A patent/RU2010138638A/ru not_active Application Discontinuation
- 2009-03-06 CA CA2718463A patent/CA2718463A1/en not_active Abandoned
- 2009-03-06 AU AU2009224613A patent/AU2009224613A1/en not_active Abandoned
- 2009-03-06 EP EP09719846A patent/EP2272515A1/en not_active Withdrawn
- 2009-03-06 US US12/921,933 patent/US20110027251A1/en not_active Abandoned
- 2009-03-06 CN CN2009801183670A patent/CN102036665A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518119A5 (enExample) | ||
| RU2010138638A (ru) | Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей | |
| RU2470016C2 (ru) | Производное бипиразола | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2013520405A5 (enExample) | ||
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| JP2010222367A5 (enExample) | ||
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2013542247A5 (enExample) | ||
| MX2011013201A (es) | Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2011026348A5 (enExample) | ||
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| EP2796450A4 (en) | 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| JP2011516544A5 (enExample) | ||
| UA111480C2 (uk) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ | |
| JP2011512394A5 (enExample) | ||
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| JP2008533079A5 (enExample) |